Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

5.960 -0.350 (-5.55%)
Streaming Delayed Price Updated: 3:08 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
News headline image
Psychedelic Stock Gainers And Losers From January 24, 2022 ↗
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
News headline image
Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri ↗
Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychede... 
Via Benzinga
News headline image
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD ↗
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a... 
Via Talk Markets
News headline image
Psychedelic Stock Gainers And Losers From January 21, 2022 ↗
GAINERS: GH Research (NASDAQ: 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From January 20, 2022 ↗
GAINERS: Small Pharma (OTC: 
Via Benzinga
News headline image
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
News headline image
Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows ↗
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From January 18, 2022 ↗
GAINERS: Cybin (AMEX: 
Via Benzinga
News headline image
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington ↗
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian gov... 
Via Benzinga
News headline image
Psilocybin Does Not Produce Adverse Effects On Cognition Or Emotional Function, New Study Finds ↗
A new study is shedding light on the safety profile of psilocybin, the active ingredient in so-called “magic mushrooms.&rdqu... 
Via Benzinga
News headline image
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021! ↗
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the... 
Via Talk Markets
News headline image
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around? ↗
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv... 
Via Benzinga
News headline image
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
News headline image
The Year In Review For Psychedelic Drug Stocks: 2021 ↗
2021 was two different 
Via Talk Markets
News headline image
Why Jim Cramer Likes MGM Growth Properties ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE: 
Via Benzinga
News headline image
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
News headline image
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index ↗
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
News headline image
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms ↗
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
News headline image
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline ↗
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
News headline image
Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways ↗
Coda Signature Taps Teddy C. Scott As Board Member Producer of cannabis-infused edibles and wellness products Coda Signature 
Via Benzinga
Topics Cannabis
News headline image
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers ↗
In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “ 
Via Benzinga
News headline image
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November ↗
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
News headline image
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction ↗
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher... 
Via Benzinga
News headline image
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways ↗
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ... 
Via Benzinga
News headline image
Were Compass Pathways' Clinical Trial Results Really That Bad? ↗
The biotech was priced for perfection; its data wasn't. 
Via The Motley Fool
News headline image
10 Biggest Price Target Changes For Monday ↗
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
News headline image
Better Buy: Compass Pathways vs. Jazz Pharmaceuticals ↗
Both of these biotech stocks are innovators, but one is more likely to hit it out of the park. 
Via The Motley Fool
News headline image
Psychedelic Drug Stocks Continued To Decline Last Week ↗
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
News headline image
How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions ↗
Image by Mathew Schwartz from Unsplash The following post was written and/or pu... 
Via Benzinga
News headline image
Is Now the Right Time to Buy Compass Pathways? ↗
Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.